CD4 Gene - CD4 Molecule | T-Cell Co-Receptor and HIV Receptor
Complete genetic, functional, and clinical reference for the CD4 gene, including expression data, mutations, and disease associations.
Gene Information Card
| Symbol | CD4 |
|---|---|
| Full Name | CD4 molecule |
| Gene Type | protein coding |
| Chromosomal Location | 12p13.31 |
| NCBI Gene ID | 920 ncbi.nlm.nih.gov/gene/920 |
| Ensembl ID | ENSG00000010610 |
| UniProt ID | P01730 |
| OMIM ID | 186940 |
| HGNC ID | 1678 |
| Aliases | CD4 antigen, T-cell surface glycoprotein CD4, T-cell differentiation antigen L3T4, OKT4 |
Description
The CD4 gene encodes the CD4 protein, a single-pass type I membrane glycoprotein that serves as a co-receptor for the T-cell receptor (TCR) on helper T cells. It is essential for the recognition of antigens presented by MHC class II molecules on antigen-presenting cells. CD4 also functions as the primary high-affinity receptor for the human immunodeficiency virus (HIV), facilitating viral entry into host cells. The protein is composed of four immunoglobulin-like domains (D1-D4), with the D1 domain binding to the beta-2 domain of MHC class II and the gp120 envelope protein of HIV. CD4 is expressed on the surface of helper T cells, regulatory T cells, monocytes, macrophages, and dendritic cells. Its expression is critical for the development and function of the adaptive immune system.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| HIV/AIDS | CD4 serves as the primary receptor for HIV-1 and HIV-2. The viral gp120 envelope protein binds to the D1 domain of CD4, triggering a conformational change that allows co-receptor (CCR5 or CXCR4) binding and subsequent viral entry. Progressive depletion of CD4+ T cells leads to immunodeficiency. | OMIM 186940; NCBI Gene |
| Idiopathic CD4 Lymphopenia | A rare syndrome characterized by persistently low CD4+ T-cell counts (<300 cells/µL) without evidence of HIV infection. Genetic variants in CD4 or other immune-related genes may contribute to impaired T-cell development or survival, though the exact mechanism is often unclear. | OMIM 186940; ClinVar |
| Immunodeficiency 65 | A rare primary immunodeficiency caused by homozygous mutations in the CD4 gene, leading to a complete absence of CD4 expression on T cells. This results in impaired T-cell help, reduced antibody responses, and increased susceptibility to infections. | OMIM 186940; ClinVar |
| Cutaneous T-Cell Lymphoma | CD4 is expressed on malignant T cells in mycosis fungoides and Sézary syndrome. The CD4 expression is used as a diagnostic marker and therapeutic target, though the gene itself is not typically mutated. | COSMIC; NCBI Gene |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Spleen | 17.2 | High |
| Lymph Node | 15.8 | High |
| Blood | 14.5 | High |
| Bone Marrow | 8.3 | Medium |
| Lung | 4.1 | Low |
| Small Intestine | 3.2 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| Jurkat (T-cell leukemia) | 25.4 | High expression; commonly used model for T-cell signaling |
| MOLT-4 (T-cell leukemia) | 22.1 | High expression |
| THP-1 (Monocytic leukemia) | 12.3 | Medium expression; monocyte lineage |
| U937 (Histiocytic lymphoma) | 9.8 | Medium expression; monocyte lineage |
| K-562 (CML) | 0.2 | No significant expression |
Data source:Human Protein Atlas(proteinatlas.org)
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.448C>T (p.Arg150Cys) | Missense | Rare | Disrupts D1 domain structure, impairing MHC class II binding and HIV gp120 interaction |
| c.1216C>T (p.Arg406Ter) | Nonsense | Rare | Premature truncation, leading to loss of cytoplasmic tail and impaired signaling |
| c.1A>G (p.Met1Val) | Start codon loss | Rare | Complete loss of protein expression; associated with Immunodeficiency 65 |
| c.1024_1025del (p.Leu342fs) | Frameshift | Rare | Frameshift leading to truncated protein and loss of function |
Mutation functional classification
Loss of Function (LOF)
Most CD4 mutations are loss-of-function, resulting in reduced or absent CD4 protein expression on the cell surface. This leads to impaired T-cell help, defective immune responses, and increased susceptibility to infections. Homozygous loss-of-function mutations cause Immunodeficiency 65.
Gain of Function (GOF)
No gain-of-function mutations have been reported for CD4. The protein's function is tightly regulated, and increased activity would likely lead to autoimmunity, but such variants have not been documented.
Dominant Negative (DN)
No dominant-negative mutations have been described for CD4. Since CD4 functions as a monomer on the cell surface, a single mutant allele is unlikely to exert a dominant-negative effect. Heterozygous carriers of loss-of-function mutations are typically asymptomatic.
View complete mutation data:
Gene Ontology (GO)
| • protein binding | • MHC class II protein binding |
| • coreceptor activity | • identical protein binding |
| • plasma membrane | • integral component of membrane |
| • T cell receptor signaling pathway | • cell surface receptor signaling pathway |
| • immune response | • viral entry into host cell |
Pathways
• T cell receptor signaling pathway
• HIV lifecycle
• Adaptive Immune System
• PD-1 signaling
• Costimulation by the CD28 family
Protein Summary
The CD4 protein is a 458-amino-acid type I transmembrane glycoprotein with a molecular weight of approximately 55 kDa. It consists of four extracellular immunoglobulin-like domains (D1-D4), a single transmembrane region, and a short cytoplasmic tail. The D1 domain is critical for binding to MHC class II molecules and HIV gp120. The cytoplasmic tail interacts with the tyrosine kinase Lck, which is essential for TCR signaling. CD4 is expressed on helper T cells, regulatory T cells, monocytes, macrophages, and dendritic cells. It plays a central role in the adaptive immune response by stabilizing the TCR-MHC class II interaction and enhancing T-cell activation. As the primary receptor for HIV, CD4 is a major target for therapeutic interventions, including monoclonal antibodies (e.g., ibalizumab) and entry inhibitors.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| CD40 Knockout HEK293 Cell Line | EDJ-KQ553 | Human | 958 | Details Get a Quote |
| CD40LG Knockout HEK293 Cell Line | EDJ-KQ554 | Human | 959 | Details Get a Quote |
| PLCD4 Knockout HEK293 Cell Line | EDJ-KQ1617 | Human | 84812 | Details Get a Quote |
| CD47 Knockout HEK293 Cell Line | EDJ-KQ1969 | Human | 961 | Details Get a Quote |
| CD44 Knockout HEK293 Cell Line | EDJ-KQ3375 | Human | 960 | Details Get a Quote |
| PDCD4 Knockout HEK293 Cell Line | EDJ-KQ3907 | Human | 27250 | Details Get a Quote |
| ABCD4 Knockout HEK293 Cell Line | EDJ-KQ5612 | Human | 5826 | Details Get a Quote |
| C2CD4C Knockout HEK293 Cell Line | EDJ-KQ8148 | Human | 126567 | Details Get a Quote |
| C2CD4A Knockout HEK293 Cell Line | EDJ-KQ10451 | Human | 145741 | Details Get a Quote |
| HACD4 Knockout HEK293 Cell Line | EDJ-KQ11639 | Human | 401494 | Details Get a Quote |
| C2CD4B Knockout HEK293 Cell Line | EDJ-KQ12602 | Human | 388125 | Details Get a Quote |
| C2CD4D Knockout HEK293 Cell Line | EDJ-KQ12603 | Human | 100191040 | Details Get a Quote |
| CD4 Knockout HEK293 Cell Line | EDJ-KQ17684 | Human | 920 | Details Get a Quote |
| CD48 Knockout HEK293 Cell Line | EDJ-KQ17741 | Human | 962 | Details Get a Quote |
| CD46 Knockout HEK293 Cell Line | EDC09605 | Human | 4179 | Details Get a Quote |
Displaying Records 1 To 15 Of 72 Records
- 1
- 2
- Next Page »